NCT06065813

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

The Efficacy and Safety of Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIB-IIIA Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Northern Jiangsu People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Conditions

• Non-small Cell Lung Cancer
• Neoadjuvant Therapy
• Radiotherapy
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Toripalimab	200 mg Toripalimab intravenously every 3 weeks 3 doses of Toripalimab before operation 14 doses of Toripalimab 30 days after operation
RADIATION	Conventional segmental radiotherapy	the does of radiation will be 40-45Gy. The day of the first dose of Toripalimab and the first day of radiation must be the same day.
OTHER	opreation	The operable patients will accept radical operated in 28-42 days after the third dose of Toripalimab

Timeline

• Start date: 2022-08-08
• Primary completion: 2026-05-30
• Completion: 2026-05-30
• First posted: 2023-10-04
• Last updated: 2023-10-04

Locations

1 site across 1 country: China